Genexine, Inc. (095700.KQ)
KRW 5590.0
(-3.79%)
KRW 5590.0
(-3.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -41.24 Billion KRW | -21.84% |
| 2022 | -34.41 Billion KRW | -35.1% |
| 2021 | -25.47 Billion KRW | 41.66% |
| 2020 | -43.66 Billion KRW | 6.33% |
| 2019 | -46.61 Billion KRW | -9.01% |
| 2018 | -42.76 Billion KRW | -59.22% |
| 2017 | -26.85 Billion KRW | 13.04% |
| 2016 | -30.88 Billion KRW | -2942.32% |
| 2015 | 1.08 Billion KRW | 0.0% |
| 2012 | -2.68 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.69 Billion KRW | 47.03% |
| 2024 Q1 | -12.64 Billion KRW | -361.22% |
| 2023 Q2 | -11.99 Billion KRW | -5.33% |
| 2023 FY | -41.92 Billion KRW | -21.84% |
| 2023 Q4 | -2.74 Billion KRW | 82.65% |
| 2023 Q3 | -15.8 Billion KRW | -31.73% |
| 2023 Q1 | -11.39 Billion KRW | 15.57% |
| 2022 Q4 | -13.49 Billion KRW | -58.72% |
| 2022 FY | -34.41 Billion KRW | -35.1% |
| 2022 Q1 | -3.02 Billion KRW | 78.78% |
| 2022 Q3 | -8.5 Billion KRW | 9.49% |
| 2022 Q2 | -9.39 Billion KRW | -210.13% |
| 2021 Q1 | 10.97 Billion KRW | 187.16% |
| 2021 FY | -25.47 Billion KRW | 41.66% |
| 2021 Q2 | -11.56 Billion KRW | -205.4% |
| 2021 Q3 | -8.23 Billion KRW | 28.83% |
| 2021 Q4 | -14.27 Billion KRW | -73.32% |
| 2020 Q3 | -11.87 Billion KRW | -21.59% |
| 2020 FY | -43.66 Billion KRW | 6.33% |
| 2020 Q2 | -9.76 Billion KRW | -99.04% |
| 2020 Q4 | -12.59 Billion KRW | -6.01% |
| 2020 Q1 | -4.9 Billion KRW | 62.61% |
| 2019 Q2 | -13.68 Billion KRW | -7.21% |
| 2019 FY | -46.61 Billion KRW | -9.01% |
| 2019 Q4 | -13.12 Billion KRW | -162.81% |
| 2019 Q3 | -4.99 Billion KRW | 63.49% |
| 2019 Q1 | -12.76 Billion KRW | 0.0% |
| 2018 FY | -42.76 Billion KRW | -59.22% |
| 2017 FY | -26.85 Billion KRW | 13.04% |
| 2016 FY | -30.88 Billion KRW | -2942.32% |
| 2015 FY | 1.08 Billion KRW | 0.0% |
| 2013 Q3 | -1.51 Billion KRW | 0.0% |
| 2012 Q3 | -955.44 Million KRW | 0.0% |
| 2012 FY | -2.68 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 67.014% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -1155.446% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 4056.859% |
| Bioneer Corporation | 791.75 Million KRW | 5308.808% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -712.814% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | -64.106% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | -33.41% |
| Helixmith Co., Ltd | -35.24 Billion KRW | -17.011% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | -337.56% |
| Medy-Tox Inc. | 17.32 Billion KRW | 338.079% |
| Peptron, Inc. | -15.6 Billion KRW | -164.315% |
| Amicogen, Inc. | 2.05 Billion KRW | 2105.742% |
| HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -374.019% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 48.973% |
| ALTEOGEN Inc. | -9.73 Billion KRW | -323.555% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 140.907% |
| SillaJen, Inc. | -21.34 Billion KRW | -93.203% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 1665.928% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | -126.781% |
| Genomictree Inc. | -17.3 Billion KRW | -138.339% |
| MedPacto, Inc. | -28.75 Billion KRW | -43.436% |
| D&D Pharmatech | -13.48 Billion KRW | -205.799% |
| EASY BIO,Inc. | 20.63 Billion KRW | 299.896% |
| GI Innovation, Inc. | -55.6 Billion KRW | 25.831% |